Howard Gadi, Weiner Dror, Bar-Or Itzhak, Levine Arie
Pediatric gastroenterology and nutrition unit, Wolfson Medical Center, Holon, Israel.
Sackler School of Medicine, Tel-Aviv University.
Eur J Gastroenterol Hepatol. 2022 Apr 1;34(4):372-374. doi: 10.1097/MEG.0000000000002203.
There is a paucity of treatment options for patients who have failed multiple biologics. A drawback of biologic therapies is their selectivity in targeting a single pathway. We report the use of dual biologic therapy with vedolizumab and ustekinumab for three highly refractory patients who previously failed both of these medications as monotherapy. The dual biologic therapy led to the closure of a recto-vaginal fistula and restoration of continuity after takedown of a stoma.
对于多种生物制剂治疗无效的患者，治疗选择匮乏。生物疗法的一个缺点是其在靶向单一通路方面的选择性。我们报告了对三名高度难治性患者使用维多珠单抗和优特克单抗进行双重生物疗法，这三名患者之前单独使用这两种药物均治疗失败。双重生物疗法使直肠阴道瘘闭合，并在造口拆除后恢复了连续性。
